Barclays

Barclays’s Arcutis Biotherapeutics ARQT Stock Holding History

Barclays’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$682K	Sell	28,965 -302,613	-91%	-$7.72M	﹤0.01%	2993
2025 Q4	$9.63M	Buy	331,578 +5,610	+2%	+$144K	﹤0.01%	1709
2025 Q3	$6.14M	Sell	325,968 -68,073	-17%	-$1.07M	﹤0.01%	2035
2025 Q2	$5.52M	Buy	394,041 +199,269	+102%	+$2.79M	﹤0.01%	2039
2025 Q1	$3.05M	Sell	194,772 -43,169	-18%	-$608K	﹤0.01%	2312
2024 Q4	$3.31M	Sell	237,941 -15,451	-6%	-$169K	﹤0.01%	2507
2024 Q3	$2.36M	Buy	253,392 +151,279	+148%	+$1.49M	﹤0.01%	2722
2024 Q2	$950K	Buy	102,113 +3,608	+4%	+$32.6K	﹤0.01%	2628
2024 Q1	$976K	Sell	98,505 -10,155	-9%	-$75.8K	﹤0.01%	3144
2023 Q4	$351K	Sell	108,660 -98,417	-48%	-$268K	﹤0.01%	4107
2023 Q3	$1.1M	Sell	207,077 -26,341	-11%	-$224K	﹤0.01%	2266
2023 Q2	$2.22M	Sell	233,418 -1,096,647	-82%	-$12.2M	﹤0.01%	1821
2023 Q1	$14.6M	Buy	1,330,065 +149,681	+13%	+$2.17M	0.02%	987
2022 Q4	$17.5M	Buy	1,180,384 +1,039,547	+738%	+$18.2M	0.02%	951
2022 Q3	$2.69M	Buy	140,837 +106,001	+304%	+$2.4M	﹤0.01%	1543
2022 Q2	$742K	Sell	34,836 -3,102	-8%	-$63.6K	﹤0.01%	2563
2022 Q1	$730K	Buy	+37,938	New	+$642K	﹤0.01%	2635

Other funds holding ARQT

Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return

Jennison Associates

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return